This is not a 1 cent stock. I’ve explained multiple times that you don’t derive valuation from a singular purchase. The most we can say is that valuation is currently incomplete, as the most relevant reports haven’t been released yet (annual/q1).
Also, CareClix is in its infancy from SOLI’s perspective. We don’t know what impact recent deals have had, nor the impact of a larger sales staff.
Dilution has been an issue, but the share issuances are mostly from employee compensation and known convertibles. The majority is still restricted.